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Spinal muscular atrophy (SMA) is an inherited neuromuscular disease primarily
characterized by degeneration of spinal motor neurons, and caused by reduced levels
of the SMN protein. Previous studies to understand the proteomic consequences of
reduced SMN have mostly utilized patient fibroblasts and animal models. We have
derived human motor neurons from type I SMA and healthy controls by creating their
induced pluripotent stem cells (iPSCs). Quantitative mass spectrometry of these cells
revealed increased expression of 63 proteins in control motor neurons compared to
respective fibroblasts, whereas 30 proteins were increased in SMA motor neurons vs.
their fibroblasts. Notably, UBA1 was significantly decreased in SMA motor neurons,
supporting evidence for ubiquitin pathway defects. Subcellular distribution of UBA1 was
predominantly cytoplasmic in SMA motor neurons in contrast to nuclear in control motor
neurons; suggestive of neurodevelopmental abnormalities. Many of the proteins that were
decreased in SMAmotor neurons, including beta III-tubulin and UCHL1, were associated
with neurodevelopment and differentiation. These neuron-specific consequences of SMN
depletion were not evident in fibroblasts, highlighting the importance of iPSC technology.
The proteomic profiles identified here provide a useful resource to explore the molecular
consequences of reduced SMN in motor neurons, and for the identification of novel
biomarker and therapeutic targets for SMA.
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INTRODUCTION
Spinal Muscular Atrophy (SMA) is a recessively inherited neuromuscular disease displaying a wide
range of severity, from the most severe Type I (diagnosed somewhere between birth to 6 months of
age), to adult onset, Type IV. SMA is primarily characterized by loss of function and degeneration
of lower motor neurons in the anterior horn of the spinal cord, and is caused by reduced levels of
the survival of motor neurons (SMN) protein, which is encoded by two genes, SMN1 and SMN2
Fuller et al. Proteomics on SMA Patient Motor Neurons
(Lefebvre et al., 1995). Most of the mRNA transcribed from the
SMN2 gene is alternatively spliced to omit exon 7 and any protein
translated from such “delta7” mRNA is unstable and rapidly
degraded (Lefebvre et al., 1995; Lorson et al., 1998; Pellizzoni
et al., 1999). In SMA patients, the SMN1 gene is mutated or
deleted and only a small amount of stable and functional SMN is
produced from the SMN2 gene, with the more severe phenotypes
having the least SMN (Coovert et al., 1997; Lefebvre et al., 1997).
SMN is a ubiquitously-expressed protein that plays a central
role RNA biogenesis; regulating the assembly of small nuclear
ribonucleic proteins (snRNPs) in the cytoplasm and their
subsequent transport into the nucleus (Lefebvre et al., 1995;
Pellizzoni et al., 1998). Aside from this housekeeping role,
SMN also appears to have a neuronal-specific role in mRNA
processing, where it interacts with hnRNP-R to transport β-
actin mRNA in axons (Rossoll et al., 2003; Carrel et al., 2006).
Despite this knowledge about the cellular functions of SMN, it
has become clear, from studies with mouse models, that defects
in RNA splicing or axonal transport do not fully explain why
lower motor neurons are particularly vulnerable to reduced levels
of SMN (Kariya et al., 2008; Burghes and Beattie, 2009; Murray
et al., 2010; Sleigh et al., 2011; Hamilton and Gillingwater, 2013).
Previous attempts to understand the molecular consequences
of reduced SMN expression in SMA have largely been focused
on patient fibroblasts and animal models. Various animal models
of SMA are available (Edens et al., 2015), but their intrinsic
differences from humans may prevent effective translation to
clinical trials. In addition, animal models of SMA may not
be as amenable to high-throughput drug discovery programs,
compared to patient cells. SMA patient skin fibroblasts are
easily accessible and can be expanded in culture, in large
quantities, with relative ease. Although, SMA patient skin
fibroblasts display reduced SMN levels in culture, the skin itself
is pathophysiologically spared in patients, suggesting that these
cells respond differently to, or have different requirements for,
SMN, compared with lower motor neurons.
Reprogramming somatic cell types to pluripotency by human
induced pluripotent stem cell (iPSC) technology preserves the
patient’s genome and its errors and allows investigators to observe
these diseased genotypes within any human cell type (Takahashi
et al., 2007; Yu et al., 2007). Human iPSCs can provide an
unlimited supply of patient cells (e.g., lower motor neurons for
SMA), which can then be studied in vitro. We have previously
shown that iPSCs from type I SMA patients are capable of
differentiating into motor neurons that lack SMN1 expression
and demonstrate selective motor neuron death over time (Ebert
and Svendsen, 2010; Sareen et al., 2012; Barrett et al., 2014).
Whilst targeted biochemical studies enable the characterization
of known protein pathways in such cellular models, large-scale
quantitativemass spectrometry approaches offer the possibility of
studying the proteome in an unbiased fashion, and can be useful
for assessing the suitability of cellular models (Hornburg et al.,
2014).
The aim of this study was to conduct the first comprehensive
evaluation of the proteome of SMA patient iPSC-derived
motor neurons and provide a comparison against genetically
matched fibroblasts using quantitative mass spectrometry (i.e.,
iTRAQ). We were particularly interested to examine whether
there are down-stream effects of reduced SMN in iPSC-derived
motor neuron cultures, not found in fibroblasts, as these
could be useful for exploring the particular vulnerability of
motor neurons in SMA. In a 4-plex quantitative proteomics
comparison (iTRAQ), we compared the proteome of SMA
and control motor neurons with the fibroblast cell lines from
which they were originally derived. We provide evidence that
motor neurons from SMA patients display reduced expression of
proteins involved in developmental and differentiation pathways,
including ubiquitin-activating enzyme 1 (UBA1) and ubiquitin
carboxyl-terminal esterase L1 (UCHL1), and that most of these
changes are distinct from those seen in the fibroblast cell lines
from which the iPSCs were derived.
METHODS
Ethics Statement
Human dermal fibroblasts or lymphoblastoid cell lines (LCLs)
were obtained from the Coriell Institute for Medical Research.
The Coriell Cell Repository maintains the consent and privacy
of the donor LCLs. All the cell lines and protocols in
the present study were carried out in accordance with the
guidelines approved by Stem Cell Research Oversight committee
(SCRO) and Institutional Review Board (IRB) at the Cedars-
Sinai Medical Center under the auspice IRB-SCRO Protocols
Pro00032834 (iPSC Core Repository and Stem Cell Program),
Pro00024839 (Using iPS cells to develop novel tools for
the treatment of SMA) and Pro00036896 (Sareen Stem Cell
Program).
Generation of Human iPSCs Using
Episomal Plasmids
Human iPSCs were generated as described previously (Sareen
et al., 2012, 2013, 2014; Barrett et al., 2014). Briefly, iPS
cell lines were reprogrammed from dermal fibroblasts into
virus-free iPSC lines with the Nucleofector Kit using 1.5µg
of each episomal plasmid (Addgene) expressing six factors:
OCT4, SOX2, KLF4, L-MYC, LIN28, and p53 shRNA (pCXLE-
hOCT3/4-shp53-F, pCXLE-hUL, and pCXLE-hSK). This method
has a significant advantage over viral transduction because
exogenously introduced genes do not integrate and are instead
expressed episomally in a transient fashion. Dermal fibroblasts
(1 × 106 cells per nucleofection) were harvested, centrifuged
at 1500 rpm for 5min, re-suspended carefully in Nucleofector R©
Solution and the U-023 program was applied. These nucleofected
cells were plated on feeder-independent BD Matrigel™ growth
factor-reduced Matrix (Corning/BD Biosciences, #354230). All
cultures were maintained at 20% O2 during the reprogramming
process. Individual iPSC colonies with ES/iPSC-like morphology
appeared between day 25 and 32 and those with best morphology
were mechanically isolated, transferred onto 12-well plates with
fresh Matrigel™ Matrix, and maintained in mTeSR R©1 medium.
The iPSC clones were further expanded and scaled up for further
analysis.
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Karyotype
The SMA and control iPS cell lines were incubated in Colcemid
(100 ng/mL; Life Technologies) for 30min at 37◦C and then
dissociated using trypsin (TrypLE) for 10min. They were then
washed in phosphate buffered saline (PBS) and incubated at 37◦C
in 5mL of hypotonic solution (1 g potassium chloride (KCl),
1 g sodium citrate in 400mL water) for 30min. The cells were
centrifuged for 2.5min at 1500 rpm and resuspended in fixative
(methanol: acetic acid, 3:1) at room temperature for 5min. This
was repeated twice, and finally cells were resuspended in 500µL
of fixative solution and submitted to the Cedars-Sinai Clinical
Cytogenetics Core for G-Band karyotyping.
Pluritest
High quality total RNA was isolated from undifferentiated iPSCs,
H9 hESCs, fibroblasts, and primary human neural progenitors
using the RNeasy Mini Kit (Qiagen) and subsequently run
on a Human HT-12 v4 Expression BeadChip Kit (Illumina).
The raw data file (idat file) was subsequently uploaded
on to an open-source and easily accessible Pluritest widget
online (www.pluritest.org). PluriTest is a transciptomics and
bioinformatics based characterization test for determining
pluripotency of a reprogrammed cell line (Müller et al., 2008–
2012). In this test mRNA expression values of all probes including
pluripotency-associated genes are scored against samples in the
stem cell model matrix, consisting of 264 pluripotent cell lines
(223 hESC and 41 human iPSC) and 204 samples derived from
somatic cells and tissues. The red and blue background hint
to the empirical distribution of the pluripotent (red) and non-
pluripotent samples (blue) in the Müller et al. (2008–2012)
test data set. An iPSC line is considered a bona-fide fully
reprogrammed pluripotent cell line when the pluripotency score
is above 20 and the novelty score is below 1.6. A typical chart
combines pluripotency score on y-axis and novelty score on
x-axis.
Neural and Motor Neuron Differentiation
The SMA patient and control subject iPSCs were grown
until ∼90% confluent as colonies under normal maintenance
conditions before the start of the differentiation. The single
cell iPSCs were gently lifted by accutase treatment for 5min at
37◦C. Subsequently, 1.5–2.5 × 104 cells were placed in each well
of a 384 well plate in defined neuroectodermal differentiation
medium (NDM) composed of Iscove’s modified Dulbecco’s
medium supplemented with B27–vitamin A (2%) and N2 (1%),
with the addition of 0.2µM LDN193189 and 10M SB431542
(NDM+LS). This is a modified dual-SMAD protocol (Chambers
et al., 2009). All days of differentiation described are post-iPSC
(PI) stage (day 0). At day 2 PI, neural aggregates were transferred
to low adherence polyhydroxyethylmethacrylate (poly-HEMA)
coated flasks and cultured in suspension. After this point,
the differentiation protocol was optimized to reliably generate
lower spinal motor neurons. At 5 days PI, neuroectodermal
aggregates were seeded on laminin-coated (50µg/mL; Sigma
#L2020) six well plates to induce neural rosette formation. From
days 12 to 19 PI, the media was changed to motor neuron
specification media (MNSM) supplemented with 0.25µM all-
trans retinoic acid (ATRA), 1µM purmorphamine, 20 ng/mL
brain-derived neurotrophic factor (BDNF), 20 ng/mL glial cell
line-derived neurotrophic factor (GDNF), 200 ng/mL ascorbic
acid, and 1µM dibutyryl cyclic adenosine monophosphate (db-
cAMP). Between days 17 and 19 PI, neural rosettes were
selected using rosette selection media (StemCell Technologies,
#05832). The isolated rosettes were subsequently cultured in
motor neuron precursor expansion media (MNPEM) consisting
of NDM, 0.1µM ATRA, 1µM purmorphamine, 100 ng/mL
EGF, and 100 ng/mL FGF2. These iPSC-derived motor neuron
precursor spheres (iMPS) can be expanded over a 2–7 week
period by an automated chopping method (Svendsen et al.,
1998). The iMPS were differentiated further for 21 and 28 days,
for maturation into into motor neurons before harvesting or
fixation. These motor neuron samples were used in iTRAQ
and other experiments described here. Briefly, iMPS were
dissociated with accutase and then seeded onto laminin-
coated plates (5–8 × 105 cells/cm2) in MN maturation media
(MNMM) stage 1 for 7 days consisting of NDM, supplemented
with 0.1µM ATRA, 1µM purmorphamine, 10 ng/mL BDNF,
10 ng/mL GDNF, 200 ng/mL ascorbic acid, 1µM db-cAMP,
and 2.5µM N-[(3,5-Difluorophenyl)acetyl]-L-alanyl-2-phenyl]
glycine-1,1-dimethylethyl ester (DAPT; inhibitor of γ-secretase;
Cayman Chemicals, #13197). The remainder of terminal
differentiation was carried out in Neurobasal supplemented with
1% NEAA, 0.5% GlutaMax, 1% N2, 10 ng/mL BDNF, 10 ng/mL
GDNF, 200 ng/mL ascorbic acid, 1µM db-cAMP, and 0.1µM.
Quantitative Proteomics Comparison
Cell pellets (containing ∼6 × 104 cells) were extracted in
four volumes of extraction buffer (w/v) containing 6M Urea,
2M Thiourea, 2% CHAPS and 0.5% SDS in HPLC-grade
water (Sigma Chromasolv plus). The extracts were sonicated
briefly and left on ice for 10min, followed by centrifugation at
13,000 × g for 10min at 4◦C to pellet any insoluble material.
The proteins were precipitated in six volumes of ice cold
acetone overnight at −20◦C. The acetone precipitates were
pelleted by centrifugation at 13,000 × g for 10min at 4◦C
and the supernatant was carefully removed and discarded. The
pellets were allowed to air-dry, and were then resuspended
in 500mM tetraethylammonium bromide (TEAB). The protein
concentration in each group was determined using a Bradford
assay.
Sample Preparation for Mass
Spectrometry Analysis
Reduction, alkylation, and digestion steps were performed
according to the recommendations detailed in the iTRAQ
labeling kit (AB Sciex). The extracts were digested with trypsin
(5µg per 100µg of protein) overnight at 37◦C, followed
by reduction and alkylation steps performed according to
instructions outlined in the iTRAQ labeling kit. The digests were
subsequently dried down in a vacuum centrifuge and iTRAQ
labeling was carried out according to the instructions in the
iTRAQ labeling kit. The iTRAQ tags were assigned to samples
as follows: 114, fibroblasts from control GMO3814 (n = 1); 115,
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motor neurons—derived from control GMO3814 (n = 1); 116,
fibroblasts from Type 1 SMA patient GMO0232 (n = 1); 117,
motor neurons—derived from Type 1 SMA patient GMO0232
(n = 1). Each tag was incubated with 60µg of total protein (as
determined by a Bradford protein assay).
Mass Spectrometry Analysis
The combined 4-plex iTRAQ labeled peptides were concentrated
in a vacuum concentrator and resuspended in 0.6mL of loading
Buffer Ascx (10mM monopotassium phosphate (KH2PO4), 20%
acetonitrile (MeCN), pH 3.0), followed by sonication. The pH
was adjusted to 3.0 with 0.5M orthophosphoric acid (H3PO4).
The peptides were then separated by strong cation exchange
chromatography as described previously (Fuller et al., 2015).
Each SCX fraction was analyzed by nanoLC ESI MSMS using
a TripleTOF 5600 tandem mass spectrometer (ABSciex, Foster
City, CA) as described previously (Fuller et al., 2015). The raw
mass spectrometry data file was subsequently analyzed using
ProteinPilot 4.5 software with the Paragon™ and ProGroup™
algorithms (ABSciex) against the human sequences in the
Swiss-Prot database (http://www.uniprot.org/, accessed in July
2013; containing 539,616 sequences in total and 20,255 human
sequences). Searches were performed using the preset iTRAQ
settings in ProteinPilot. Trypsin was selected as the cleavage
enzyme and MMTS modification of cysteines with a “Thorough
ID” search effort. ProteinPilot’s Bias correction, which assumes
that most proteins do not change in expression and corrects
for unequal mixing during the combining of labeled samples,
was applied, with ratios of 1.0234 for the 115:114 labels, 0.6653
for 116:114, and 1.2362 for 117:114. Finally, detected proteins
were reported with a Protein Threshold [Unused ProtScore
(confidence)] >0.05 and used in the quantitative analysis if
they were identified with three or more peptides with 95%
confidence or above. P-values for the iTRAQ ratios were
calculated by the ProteinPilot software. A False Discovery Rate
(FDR) analysis was also performed against a concatenated
database of forward and reverse protein sequences as a decoy
database, using the Proteomics System Performance Evaluation
Pipeline (PSPEP) in ProteinPilot, which reported 2093 proteins
above a 5% local (for a given peptide) false discovery rate
threshold and 2217 proteins above a 1% global false discovery rate
threshold.
Immunohisto/Cytochemistry
Human iPS cell lines and their differentiated cell types
were plated on glass coverslips in optical-bottom 96-
well plates (Thermo, # 165305) and subsequently fixed
in 4% paraformaldehyde (Figure 1) or acetone/methanol
(Figures 2–6). For Figure 1: cells were blocked in 5% normal
donkey serum with 0.1% Triton X-100 and incubated with
primary antibodies (Supplementary File S1) either for either 1 h
at room temperature or overnight at 4◦C. Cells were then rinsed
and incubated in species-specific AF488, AF594, or AF647-
conjugated secondary antibodies followed by Hoechst 33258
(0.5µg/mL; Sigma) to counterstain nuclei. Cells were imaged
using Molecular Devices Image Express Micro high-content
imaging system or using Leica microscopes. For Figures 2–6:
coverslips were incubated in primary antibodies (Supplementary
File S1) for 1 h at room temperature. Cells were then rinsed
and incubated for 1 h with 5µg mL−1 goat anti-mouse ALEXA
488 (Molecular Probes, Eugene, OR) or swine anti-rabbit
ALEXA 546, diluted in PBS containing 1% horse serum, 1% fetal
bovine serum, and 0.1% BSA, followed by addition of DAPI
(diamidinophenylindole 200 ng mL−1) for the final 5min of
incubation. After washing, coverslips were mounted on slides in
Hydromount (Merck). High magnification images were obtained
using a Leica SP5 confocal microscope with a 63X oil immersion
objective.
SDS-Polyacrylamide Gel Electrophoresis
and Western Blotting
Protein extracts from three separate SMA and three control
iPSC-derived motor neuron cell lines were prepared by boiling
in SDS sample loading buffer (2% SDS, 5% 2-mercaptoethanol,
62.5mM Tris-HCl, pH 6.8), for 2min. Proteins were subjected
to SDS-PAGE (Biorad) using 12.5% polyacrylamide gels. A
horizontal slice was excised from the gel (clear from the
molecular weight of proteins of interest) for staining with
Coomassie blue as an internal loading control. The proteins
on the remaining part of the gel were then transferred to
nitrocellulose membranes by western blotting. After blocking
non-specific sites with 4% powdered milk solution, membranes
were incubated with primary antibodies (Supplementary File
S1), and diluted in dilution buffer (PBS, 1% fetal bovine
serum, 1% horse serum, and 0.1% BSA). Antibody reacting
bands were visualized by development with either peroxidase-
labeled goat anti-mouse Ig or peroxidise-labeled swine anti-
rabbit Ig (1µg/mL in dilution buffer) and a chemiluminescent
detection system (West Pico or West Femto, Pierce), followed by
visualization using a Gel Image Documentation system (Biorad).
Densitometry measurements of antibody reactive bands were
derived using Image J software (v1.46) and were normalized to
the densitometry of the Coomassie stained gel, as described by
Eaton et al. (2013). For quantification of the Coomassie gel, a
rectangular box was drawn around several bands in each lane for
densitometry measurement (the details of the molecular weight
range of these bands in each case is provided in each figure). The
box was then copied and carefully pasted to the same position
for every sample lane. In instances where the image quality of
the Coomassie stained gel was low due to low protein levels
(i.e., Figures 1D, 4), the contrast was adjusted uniformly across
the gel to enhance the signal. Unpaired, heteroscedastic t-tests
were conducted (Microsoft Excel) to assess whether differences
in densitometry were statistically significant.
Quantitative RT-PCR
Total RNA was isolated from three separate SMA and three
control iPSC-derived motor neuron cell lines using the Quick-
RNA MiniPrep kit (Zymo Research). A volume of 2µg of
RNA was reverse transcribed using a High Capacity cDNA
Reverse Transcription Kit by Applied Biosystems. Reactions were
performed in triplicate using SYBR Select Master Mix (Applied
Biosystems) using specific primer sequences (Supplementary File
S3). Samples were held at 50◦C for 2min, 95◦C for 2min, and
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FIGURE 1 | Characterization of iPSC line and neuronal cultures representative of a healthy control and SMA Type 1 patient iPSC line. (A) Representative
positive immunostaining for nuclear and surface pluripotency antigens with normal G-band karyotype of the iPS cells shown at the right. (B) Gene-chip and
bioinformatics based PluriTest characterization of control and SMA iPS cell lines used in this study. H9 human embryonic stem cells (hESCs) were used as positive
control, while human dermal fibroblasts and primary human neural progenitor cells (hNPCs) were negative controls. (C) Upon neuronal induction and differentiation to
the cultures analyzed contain: few Nestin progenitors (<10%) and Map2 a/b neurons (dendritic marker), pan-neurons marker beta III-tubulin (>60%) with few astroglial
(GFAP) cells, mostly SMI32- and ISL1 (Islet-1) positive motor neurons (∼40%). Nkx6.1 and ChAT are spinal motor neuron markers that are expressed in both control
and SMA-derived motor neurons. Scale bar for A is 75µm. Scale bar for C is 200µm. (D) Representative western blot showing SMN protein levels in three different
control and SMA motor neuron cell lines, along with Coomassie stained gel as loading control. The graph represents mean integrated density of SMN bands from this
blot/total protein (Coomassie gel), as determined by ImageJ software. Error bars represent standard error from the mean and statistical significance was calculated
using an unpaired, one-tailed t-test with two-sample unequal variance. Please note that the Coomassie loading control shown here is the same that is shown for
Figure 4A because they were both derived from the same blot. (E) Average gene expression levels of full-length (FL)-SMN in the control and SMA motor neurons [the
same six cell lines shown in (D)], as determined by qRT-PCR (p = 0.002; unpaired, one-tailed t-test). Relative fold expression was normalized to H9 hESCs. Error bars
represent standard error from the mean. **p ≤ 0.01.
then cycled 40 times between 95◦C for 15 s and 60◦C for 30 s. A
melting curve was recorded from 65 to 95◦C in 0.5◦C increments
over 0.05 s steps. Expression of target genes was normalized to the
expression of RPL13 ribosomal Protein L13A and calculated by
the DDCTmethod (Livak and Schmittgen, 2001; Schmittgen and
Livak, 2008). Unpaired, one-tailed t-tests were conducted using
Graphpad Prism software, to assess the statistical significance of
the expression data.
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FIGURE 2 | SMN depletion has contrasting downstream effects on the proteome of motor neurons compared to genetically matched fibroblasts. While
99 proteins were differentially expressed with statistical significance when SMA motor neurons (n = 1) were quantitatively compared to control motor neurons (n = 1)
(A), only 18 proteins were differentially expressed when SMA fibroblasts (n = 1) were quantitatively compared to control fibroblasts (n = 1) (B). Of one these 18
proteins, only one was also differentially expressed in the same direction with statistical significance when the SMA MNs were compared to control MNs, and six of the
18 proteins were differentially expressed in one direction (i.e., up- or down-regulated) when SMA fibroblasts were compared to control fibroblasts and then expressed
in the opposite direction when SMA MNs were compared to control MNs (C) (arrows indicate proteins that were verified biochemically). Plot (C) was generated using
Plotly software (Plotly Technologies Inc. (2015), https://plot.ly).
RESULTS
Generation of Human Induced Pluripotent
Stem Cell-Derived Motor Neurons
Induced pluripotent stem cells (iPSCs) generated from type I
SMA patients and healthy controls (see Supplementary File S2 for
origin, clinical history, and genetics) were generated as previously
described (Barrett et al., 2014). Positive immunostaining
confirmed the presence of nuclear and surface pluripotency
antigens, along with normal G-band karyotype (Figure 1A). A
gene-chip and bioinformatics based PluriTest (Müller et al.,
2008–2012) characterization of the control and SMA iPS cell
lines confirmed pluripotency in all SMA and control iPSC lines
(determined by the presence of a PluriTest score of >20 in
pluripotency and below 1.6 in novelty; Figure 1B). The red cloud
and surrounding region signifies pluripotent samples, while
anything outside the red cloud and in the blue area are non-
pluripotent samples, based on well-characterized pluripotent
stem cell data set (Müller et al., 2008–2012). The SMA and
control iPSCs were then directed toward a lower spinal motor
neuron fate by following stepwise differentiation paradigm
mimicking human spinal cord development. The iPSCs first
underwent neuroectodermal specification followed by addition
of caudo-ventralizing factors (all-trans retinoic acid and sonic
hedgehog agonist, purmorphamine) and maturation. At this
point, the motor neurons are electrophysiologically active, as we
have demonstrated previously (Sareen et al., 2013). These motor
neuron cultures contained few nestin progenitors and Map2 a/b
neurons (dendritic marker) (<10%), pan-neurons marker βIII-
tubulin (>60%) with few astroglial (GFAP) cells, and mostly
SMI32 and ISL1 (Islet-1) positivemotor neurons (∼40%). Nkx6.1
and ChAT are spinal motor neuron markers that are expressed in
both control and SMA-derived motor neurons (Figure 1C).
SMN Depletion has Contrasting
Downstream Effects on the Proteome of
Motor Neurons Compared to Genetically
Matched Fibroblasts
To determine the downstream proteomic consequences of
reduced SMN in iPSC-derived motor neuron cultures, we
conducted a 4-plex quantitative comparison of the proteome
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of 32i SMA motor neurons with 14i control motor neurons,
alongside the fibroblast cell lines from which they were
originally derived (i.e., GM00232 and GM03814) using iTRAQ-
mass spectrometry. This approach detected (and subsequently
quantified) 2093 proteins, with a 5% local false discovery rate
threshold (Supplementary Table 1). Even with the very latest
technology, identification of proteins using mass spectrometry
is limited to approximately the top 30% of the total proteome
(Hornburg et al., 2014). It is possible, therefore, that due to the
limitations of the technique, some important changes may not
have been detected. For example, neither SMN nor any other
known components of the SMN core complex were among the
2093 proteins that were detected and quantified, presumably
because the SMN core complex appears to be aminor component
of the entire cellular proteome (Fuller et al., 2010). Nonetheless,
a statistically significant reduction of SMN protein in the SMA
motor neurons was verified by western blotting (Figure 1D) and
a reduction of full-length SMN gene expression was verified by
RT-PCR (Figure 1E). A reduction of the SMN-binding protein,
gemin2, was also seen by western blot analysis (Supplementary
File S4), and is consistent with previous reports showing reduced
levels of SMN complex components in SMA (e.g., Hao et al.,
2007).
For reliable quantification, proteins identified from fewer
than three peptides were excluded from the list, followed
by exclusion of those with average iTRAQ ratios of <1.25
or <0.75, and finally exclusion of those with a p > 0.05.
It is possible that the filtering criteria applied here may have
resulted in some genuinely differentially expressed proteins
being omitted from the final analysis, and so we have supplied
supplementary tables of raw data to enable researchers to
analyse the data differently, or to select other protein targets
for further study (Supplementary Tables 1, 2). After applying
the filtering criteria, 99 proteins were differentially expressed,
with statistical significance, when SMA motor neurons were
compared to control motor neurons (bold; Supplementary Table
1A and Figure 2A). The differential expression of several of
the 99 proteins can be attributed to presence of some GFAP
positive astrocytes, desmin-positive myoblasts in the original
fibroblasts and collagen VI positive cells (Supplementary File
S5). Although, an equal total protein concentration was loaded
onto each iTRAQ tag, it is not yet possible to derive precisely
synchronized, homogeneous populations of mature neurons
from iPS cells.
When SMA fibroblasts were quantitatively compared to
control fibroblasts, 18 proteins were differentially expressed
(Supplementary Table 1B; bold font and Figure 2B).
Interestingly, only one of these 18 proteins, collagen alpha-
3VI, was also differentially expressed in the same direction
when the SMA motor neurons were compared to control
motor neurons (p = 0.00004) (Supplementary Table 1 and
Figure 2). Six of the 18 proteins were differentially expressed
in one direction (i.e., up- or down-regulated) when SMA
fibroblasts were compared to control fibroblasts and then
expressed in the opposite direction when SMA MNs were
compared to control MNs (Table 1, Supplementary Table 1 and
Figure 2).
Dysregulation of Developmental and
Differentiation Pathways in SMA Motor
Neurons
A quantitative comparison of protein expression in the control
motor neurons compared to their respective genetically matched
fibroblast cells revealed that 175 proteins were differentially
expressed, whereas just 82 proteins were differentially expressed
in the SMA motor neurons when compared to the fibroblasts
from which they were derived (Supplementary Tables 1C,D,
2A–C). Only 55 of these differentially expressed proteins were
common to both the SMA and the control cells; of these, 17
proteins were increased in expression in the motor neurons
compared to the fibroblast cells (Supplementary Tables 2A–C and
Figure 3A).
To gain some insight into the likely functions of the 46
proteins that were increased in expression only in the control
motor neurons vs. control fibs (and not increased in the SMA
motor neurons vs. SMA fibs), gene ontology analysis was
performed using the the Database for Annotation, Visualization
and Integrated Discovery (DAVID; Huang et al., 2009a,b).
Functional annotations that were assigned to fewer than three
proteins and with a p > 0.05 were eliminated from the list.
A clear enrichment of proteins of mitochondrial origin was
detected, along with enriched biological process terms associated
with neuronal development and differentiation (Figure 3B).
The significant reduction of one such protein, beta III-tubulin
(TBB3), to approximately one third of normal levels in three
individual SMA motor neuron cell lines was verified by western
blotting (Figure 4A) and is in very close agreement with the
iTRAQ ratio (iTRAQ ratio 0.35; Supplementary Table 1A).
Immunocytochemistry analysis revealed a global reduction of
beta III-tubulin in both cell bodies and cellular processes of
SMA motor neurons compared to control motor neurons at the
same number of weeks of differentiation (Figure 4B). Whilst
the control motor neurons expressed beta III-tubulin at levels
of more than four times the amount of that seen in the
TABLE 1 | Differentially-expressed proteins with opposite expression
levels in SMA fibroblasts compared to SMA motor neurons from the same
patient.
Protein Accession Sequence Avg. iTRAQ Avg. iTRAQ
name number coverage ratio (SMA fibs ratio (SMA MNs
(%) /CTR fibs) /CTR iMNs)
Myosin-3 P11055 52.5 [122] 0.75 5.95
Caldesmon Q05682 42.0 [23] 0.71 1.92
Zyxin Q15942 27.1 [18] 0.72 1.47
Synaptopodin-2 Q9UMS6 10.0 [3] 0.66 1.38
UCHL1 P09936 56.1 [37] 1.40 0.68
CNP P09543 30.6 [3] 1.41 0.54
Differentially-expressed proteins that were changed in one direction (i.e., up- or down-
regulated) when SMA fibroblasts were compared to control fibroblasts, but changed
in the opposite direction when SMA motor neurons were compared to control motor
neurons. Only statistically significant differential expression (i.e., those with p < 0.05)
are shown. Abbreviations in column headings refer to the following: protein name, given
name in Swiss-Prot database; [n], number of unique peptides used for quantification; fibs,
fibroblasts; SMA MNs, 32i motor neurons; CTR MNs, 14i control motor neurons.
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FIGURE 3 | Perturbation of developmental and differentiation pathways in SMA motor neurons. (A) A Venn diagram and bar chart illustrates the number of
differentially expressed proteins seen in control motor neurons (n = 1) compared to control fibroblasts (n = 1) (blue circle and blue bars) and SMN motor neurons
(n = 1) compared SMA fibroblasts (n = 1) (green circle and green bars). (B) Bioinformatics analysis of the 46 proteins that were only increased in the control motor
neurons vs. control fibs was conducted using the Database for Annotation, Visualization and Integrated Discovery (DAVID). CTR, control; MNs, motor neurons.
control genetically matched fibroblasts (iTRAQ ratio of 4.36),
beta III-tubulin levels were not significantly increased in the
SMA motor neurons compared to their respective, genetically-
matched, fibroblasts (iTRAQ ratio 1.13; not significant). This
was despite the fact that motor neuron and pan-neuronal
markers were clearly evident and similar in these cells (Figure 1).
These findings correlate well with previous work showing a
1.3- to 1.4-fold reduction in the total number of processes in
the SMA motor neurons at late stages of differentiation (i.e.,
7–10 weeks) compared to control motor neurons (Sareen et al.,
2012).
Ubiquitin Carboxyl-Terminal Esterase L1 is
Decreased in SMA Motor Neurons
Another protein that was implicated in neuronal development
(Figure 3B) (that was increased only in control motor neurons
vs. control fibs), and of some interest already to SMA, is
ubiquitin carboxyl-terminal esterase L1 (UCHL1). UCHL1 was
among the six proteins that were differentially expressed in one
direction (i.e., up- or down-regulated) when SMA fibroblasts
were compared to control fibroblasts and then expressed in the
opposite direction when SMA motor neurons were compared
to CTR motor neurons (Table 1). Levels of UCHL1 appear to
be elevated in SMA patient fibroblasts and SMA mouse models
(Hsu et al., 2010; Wishart et al., 2014). Contrary to this, we
observed a reduction of UCHL1 levels in SMA motor neurons
compared to the control motor neurons by iTRAQ (ratio 0.68;
p = 0.049), despite the original SMA fibroblasts containing
higher levels than the control fibroblasts (ratio 1.39; p = 0.007)
(Supplementary Tables 1A,B). This observation was supported by
western blot, immunocytochemistry and qPCR analysis. Western
blot analysis of UCHL1 protein levels in three individual SMA
motor neuron cells lines, compared to three control motor
neuron cell lines showed a similar trend (Figure 5A) (ns, p =
0.10; presumably due to the variation between different cell lines).
Immunocytochemistry analysis of the 32i SMA motor neurons
also indicated lower levels of UCHL1, compared to the 14i
control motor neurons (Figure 5B). In addition, a statistically
significant reduction by ∼65% (p = 0.04) of UCHL1 gene
expression was detected in the same three SMA motor neuron
cells lines compared to the same control motor neuron cell lines
(Figure 5C).
Ubiquitin-Activating Enzyme 1 is Reduced
and Differentially Localized in SMA Motor
Neurons
Several of the differentially expressed proteins (Supplementary
Table 1A, Figure 3) have previously been reported as
Frontiers in Cellular Neuroscience | www.frontiersin.org 8 January 2016 | Volume 9 | Article 506
Fuller et al. Proteomics on SMA Patient Motor Neurons
FIGURE 4 | Reduction of beta III-tubulin levels in SMA motor neurons. (A) Representative western blot showing beta III-tubulin protein levels in three different
control and SMA motor neuron cell lines, along with Coomassie stained gel as loading control. The graph above it illustrates the average integrated density of the beta
III-tubulin bands from this blot/total protein (Coomassie gel), as determined by ImageJ software. Error bars represent standard error from the mean and statistical
significance was calculated using an unpaired, ced t-test with two-sample unequal variance. Please note that the Coomassie loading control shown here is the same
that is shown for Figure 1D because they were both derived from the same blot. (B) Representative confocal images indicate a reduction of beta III-tubulin levels in
SMI-32 positive 32i SMA motor neurons. CTR, control; MNs, motor neurons. *p ≤ 0.05.
differentially expressed in SMA, further supporting the validity
of these iPS cells as a model for SMA, as well as the overall
approach employed in this study. Calreticulin—increased here
by 1.89-fold in the SMA motor neurons compared to the control
motor neurons (Supplementary Table 1A)—was previously
shown to be increased in SMA mouse muscle, SMA fibroblasts
and SMA patient muscle biopsies by ∼1.5-fold, on average,
although considerable variability between patients was noted
(Mutsaers et al., 2013). Mutations in the ubiquitin-activating
enzyme 1 (UBA1; previously UBE1) have been reported to
cause infantile-onset X-linked SMA (SMAX2; Ramser et al.,
2008; Dlamini et al., 2013) and the levels of UBA1 were reduced
by ∼50% in SMA mouse spinal cord (Huang et al., 2009b), more
than 60% in skeletal muscle (Huang et al., 2009a) and by 50%
in SMA mouse Schwann cells (Aghamaleky Sarvestany et al.,
2014). In close agreement with this, we observed a 0.48-fold
reduction of UBA1 in the SMA motor neurons compared
to the control motor neurons by iTRAQ mass spectrometry
(Supplementary Table 1A). This reduction was verified by
western blot analysis of SMA (n = 3) and control (n = 3)
motor neuron cell lines (Figure 6A), by immunocytochemistry
in SMI32-positive cells (Figure 6B) and a similar trend was
noted by gene-expression analysis of UBA1 transcript variants
1 and 2 (in the same six cell lines used for western blotting)
(Figure 6C). In the control motor neurons, the vast majority
of UBA1 was localized to the nucleus and this was in contrast
to the mainly cytoplasmic-distribution seen in the SMA motor
neurons (Figure 6B), even in cells with relatively high levels
of SMI32 expression (fourth row, Figure 6B). It seems likely
that this represents a developmental abnormality in the SMA
motor neurons, since nuclear accumulation of UBA1 appears to
correlate with neuronal maturation (Smith-Thomas et al., 1994;
Wishart et al., 2014).
DISCUSSION
In this study, human iPSC-derived motor neurons were used to
identify motor neuron-specific down-stream effects of reduced
SMN, not found in fibroblasts, which may help to explain the
particular vulnerability of motor neurons in SMA. Here, we
provide evidence that motor neurons from SMA patients display
abnormalities in developmental and differentiation pathway
proteins, and that many of these molecular differences are
distinct from those seen in the genetically matched fibroblasts.
A new approach for gaining insight into the molecular
pathways involved the dysfunction and demise of motor neurons
in SMA has been made possible by the development of iPSC-
derivedmotor neuronmodels frommultiple SMA patients (Ebert
and Svendsen, 2010; Chang et al., 2011; Corti et al., 2012; Sareen
et al., 2012; Yoshida et al., 2015). In addition to displaying the
obvious requirements of such a model (including reduced SMN
protein and displaying the desired characterizations of diseased
motor neurons Ebert and Svendsen, 2010; Sareen et al., 2012), we
have been able to further validate the model via the identification,
at the gene and protein level, of downstream consequences of
reduced SMN that have been identified in other SMA model
systems (e.g., UBA1, Wishart et al., 2014).
Though UBA1 is probably best known as an integral player
in the ubiquitin protein-degradation pathway, this cascade
also has important regulatory functions for the differentiation,
development, and growth of neuronal cells (Hamilton and
Zito, 2013; Saritas-Yildirim and Silva, 2014). In addition to
reduced levels of UBA1, we observed differential distribution
within the cells, whereby the majority of UBA1 was localized
in the cytoplasm in SMA motor neurons, in contrast to the
mainly nuclear distribution seen in control motor neurons.
It seems likely that the differential distribution seen in the
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FIGURE 5 | Decreased UCHL1 levels in SMA motor neurons. (A) Representative western blot showing UCHL1 protein levels in three different control and SMA
motor neuron cell lines. The graph above it shows the integrated density of the UCHL1 bands from this blot/total protein (Coomassie gel), as determined by ImageJ
software. The graph to the right shows the average integrated density of the UCHL1 bands from this blot/total protein (Coomassie gel). Error bars represent standard
error from the mean and statistical significance was calculated using an unpaired, one-tailed t-test with two-sample unequal variance. (B) Representative confocal
images indicate a reduction of UCHL1 levels in SMI32 positive cells. (C) Average gene expression levels of UCHL1 in the control and SMA motor neuron cell lines [the
same six cell lines shown in (A)], as determined by qRT-PCR (p = 0.04; unpaired, one-tailed t-test). Relative fold expression was normalized to H9 hESCs. Error bars
represent standard error from the mean. CTR, control, MNs, motor neurons. *p ≤ 0.05.
SMA motor neurons represents a developmental delay or
abnormality in these cells since nuclear accumulation of UBA1
correlates with neuronal maturation and differentiation in chick
embryos (Smith-Thomas et al., 1994) and mouse motor neurons
(Wishart et al., 2014). Further support for this hypothesis comes
from a clinical case report highlighting neurodevelopmental
abnormalities in an infant with a type of SMA caused by a
mutation in the UBA1 gene (SMAX2; Dlamini et al., 2013).
Wishart et al. (2014) reported that nuclear accumulation of
UBA1 occurs in control and also SMA mouse motor neurons
sometime between postnatal day 3 (P3) and 7, by which time, a
reduction of cytoplasmic UBA1 staining intensity was noted in
the SMA mice. It will be of interest, in the future, to determine
whether the rate of subcellular redistribution of UBA1 differs
Frontiers in Cellular Neuroscience | www.frontiersin.org 10 January 2016 | Volume 9 | Article 506
Fuller et al. Proteomics on SMA Patient Motor Neurons
FIGURE 6 | Reduction and differential localization of UBA1 in SMA motor neurons. (A) Representative western blot showing UBA1 protein levels in three
different control and SMA motor neuron cell lines, along with Coomassie stained gel as loading control. The graph illustrates the average integrated density of the
UBA1 bands from this blot/total protein (Coomassie gel), as determined by ImageJ software. Error bars represent standard error from the mean and statistical
significance was calculated using an unpaired, one-tailed t-test with two-sample unequal variance. (B) Representative confocal images indicate a reduction of UBA1
levels in SMI32 positive 32i SMA motor neurons and mostly cytoplasmic distribution (in comparison to the mostly nuclear distribution seen in the 14i control (CTR)
motor neurons). (C) Average gene expression levels of UBA1 transcript variants 1 (TV1) (p = 0.14; unpaired, one-tailed t-test) and 2 (TV2) (p = 0.08; unpaired,
one-tailed t-test) in the control and SMA motor neuron cell lines [the same six patient and control cell lines shown in (A)], as determined by qRT-PCR. Relative fold
expression was normalized to H9 hESCs. Error bars represent standard error from the mean. CTR, control; MNs, motor neurons. **p ≤ 0.01.
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between SMA and control mice, and in other cell and animal
models.
Previous studies have highlighted neuro-developmental
defects in SMA in primary tissue from zebrafish, mouse models,
post-mortem patient spinal cord, and SMN-depleted germline
stem cells fromDrosophila (Simic et al., 2008; Murray et al., 2010;
Grice and Liu, 2011; Hao le et al., 2015). However, many of these
studies are limited in the fact that they were conducted using
transgenic animal models or in late-symptomatic SMA patients.
Little is known, therefore, about the precise molecular pathway(s)
underlying the series of events that lead to these abnormalities
in vivo and how well these models reflect the disease etiology
seen early on in SMA patients. The expression of beta III-tubulin
is well-known to be associated with differentiation and decreased
cell proliferation of neurons (Katsetos et al., 2003). Neural
stem cells (NSCs) from a mouse model of very severe SMA
produce fewer beta III-tubulin-positive cells, and those that
are produced, have fewer and shorter neurites; suggestive of
neurodevelopmental abnormalities (Shafey et al., 2008). Such an
observation, however, has never been confirmed in quantitative
manner in SMA patient-derived neurons. Here we describe a
global reduction of beta III-tubulin protein levels by iTRAQ,
western blotting and immunocytochemistry in SMA motor
neurons. Alongside the reduction of beta III-tubulin-positive
cells, Shafey et al. (2008) also observed an increase in the numbers
of proliferative NSCs and nestin-positive cells; implying that
these cells had not differentiated as they ought to (Shafey et al.,
2008).
The observation that UCHL1 and other proteins associated
with neuronal differentiation and development were reduced
in SMA motor neurons compared to control motor
neurons supports the hypothesis that aberrations in early
neurodevelopmental pathway proteins play a key role in SMA
pathogenesis. Although, levels of UCHL1 are increased in SMA
patient fibroblasts (Supplementary Table 1; Hsu et al., 2010)
and in mouse models (Powis et al., 2014; Wishart et al., 2014),
our results indicate that UCHL1 occurs at lower levels in SMA
motor neurons compared to control motor neurons. Though
this is the first such observation, it is not so surprising when
we consider what we know already about the role of UCHL1
in neurons. In addition to an essential role maintaining the
structure and function of the mouse neuromuscular junction
(Chen et al., 2010), patients with a loss-of-function mutation in
UCHL1 demonstrate early-onset progressive neurodegeneration
(Bilguvar et al., 2013), and more recently, UCHL1 was shown
to have a role in maintaining the viability of corticospinal
motor neurons (Jara et al., 2015). Moreover, pharmacological
inhibition of UCHL1 appears to exacerbate disease symptoms
in a mouse model of SMA, suggesting that the increased levels
seen in certain cell types may either be due to an attempted
compensatory response or that these cells respond differently
to reduced SMN, compared to motor neurons (Wiese et al.,
2004). This finding also highlights the potential complexities
of therapies for SMA aimed at restoring ubiquitin homeostasis
(Wishart et al., 2014; Powis et al., 2014).
In a recent article by Hornburg et al. (2014), proteomics
analysis was used to delineate differences between primary and
cell line mouse models of motor neuron disease. The study
placed neuronal cell line models halfway between primary motor
neurons and unrelated cell lines, in terms of the proteomic-
profile of the cells. Although, it is not possible to directly
compare the proteome of primary human motor neurons
with iPSC-derived motor neurons in a similar fashion, our
results suggest that the motor neurons used in this study
are far removed from their genetically matched fibroblasts, at
least in terms of their proteomic profile. When SMA motor
neurons were compared to control motor neurons, all but
one of the 99 differentially expressed proteins were distinct
from the differences seen when genetically matched fibroblast
cell lines were compared. The differential expression of several
of these candidates that have been implicated in SMA (i.e.,
SMN, beta III-tubulin and UBA1) have been verified here in
three separate control and SMA iPS cell lines. Our results
validate the potential of iPSC technology in identifying relevant
disease mechanisms in motor neuron diseases by a proteomics
approach and builds upon iPSC disease modeling studies that
have been limited by number of independent (non-clonal)
diseased patient cell lines (Bilican et al., 2012; Corti et al.,
2012; Donnelly et al., 2013; Chen et al., 2014; Shan et al., 2014;
Boza-Morán et al., 2015). In the future, it will be interesting
to examine this further by label-free quantitative analysis of a
larger cohort of patient-derived samples and to characterize the
molecular implications of genetic diversity/heterogeneity of the
cell lines.
Despite recent advances in our understanding of the
molecular pathways involved in SMA(d’Ydewalle and Sumner,
2015), it is still not clear why lower motor neurons, in particular,
are so vulnerable to reduced levels of SMN protein. Though
previous longitudinal analyses suggests that both SMA and
control iPS-derivedmotor neuron cultures undergo neurogenesis
at similar levels over time (Sareen et al., 2012), it is conceivable
that some proteomic differences identified here could reflect
a delay in development that may not be apparent at a later
stage, if the cells were able to “catch up” developmentally. It
is important to consider, however, that a delay in any aspect
of motor neuron development could itself be a fundamental
difference with catastrophic consequences for motor neuron
circuitry development. As such, if any proteomic changes
are due to a slower development speed, they are still likely
to be highly relevant to SMA. This notion is supported by
the fact that early postnatal delivery of AAV9-SMN rescues
the SMA mouse, while later delivery does not (Foust et al.,
2010), indicating that there is a critical developmental time
window.
The distinctly different patterns of differential expression
seen here between SMA and control motor neurons, compared
to the differential expression seen in genetically matched
fibroblasts, indicates that SMN depletion has very different
downstream consequences in different cell types. The proteomic
differences identified here, therefore, are likely to provide a
useful resource for exploring the molecular consequences of
reduced SMN in motor neurons and for the identification of
novel therapeutic targets for SMA. In particular, the robust
finding here, of depleted levels of UBA1 in iPSC-derived motor
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neurons from three separate SMA patients compared to controls,
supports a growing body of evidence (Ramser et al., 2008;
Dlamini et al., 2013; Wishart et al., 2014)to suggest that this
protein is likely to be a major contributor to pathogenesis
in SMA.
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